<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">brhejo</journal-id><journal-title-group><journal-title xml:lang="en">The BRICS Health Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>The BRICS Health Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-4700</issn><issn pub-type="epub">3034-4719</issn><publisher><publisher-name>Sechenov University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47093/3034-4700.2024.1.1.35-58</article-id><article-id custom-type="elpub" pub-id-type="custom">brhejo-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Current challenges and future development of India’s healthcare system’ towards tuberculosis free India – research evidence and programmatic initiatives</article-title><trans-title-group xml:lang="ru"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8049-7541</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Gopalan</surname><given-names>N.</given-names></name></name-alternatives><bio xml:lang="en"><p>Narendran Gopalan, Scientist F, Senior Deputy Director, Indian Council </p><p>Chennai – 600031</p></bio><email xlink:type="simple">gopalannaren@yahoo.co.in</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7462-0219</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Newtonraj</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="en"><p>Ariarathinam Newtonraj, Scientist E, Deputy Director </p><p>Chennai – 600031</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6299-8211</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Elizabeth</surname><given-names>L. K.</given-names></name></name-alternatives><bio xml:lang="en"><p>Luke Hanna Elizabeth, Scientist F, Senior Deputy Director </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9203-2664</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Shanmugam</surname><given-names>S. K.</given-names></name></name-alternatives><bio xml:lang="en"><p>Siva Kumar Shanmugam, Scientist D, Asst. Director </p><p>Chennai – 600031</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6103-0818</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Ranganathan</surname><given-names>U. D.</given-names></name></name-alternatives><bio xml:lang="en"><p>Uma Devi Ranganathan, Scientist F, Senior Deputy Director </p><p>Chennai – 600031</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1209-4062</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Muniyandi</surname><given-names>M.</given-names></name></name-alternatives><bio xml:lang="en"><p>Malaisamy Muniyandi, Scientist E, Deputy Director </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4727-4135</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Ramraj</surname><given-names>B.</given-names></name></name-alternatives><bio xml:lang="en"><p>Balaji Ramraj, Scientist E, Deputy Director </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6293-4990</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Devaleenal</surname><given-names>B.</given-names></name></name-alternatives><bio xml:lang="en"><p>Bella Devaleenal, Scientist E, Deputy Director </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7360-9736</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Venkataraman</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="en"><p>Aishwarya Venkataraman, Scientist E, Deputy Director </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7462-7066</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Nagarajan</surname><given-names>K.</given-names></name></name-alternatives><bio xml:lang="en"><p>Karikalan Nagarajan, Scientist B, Research officer </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4595-5233</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Bethunaickan</surname><given-names>R.</given-names></name></name-alternatives><bio xml:lang="en"><p>Ramalingam Bethunaickan, Scientist E, Deputy Director </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3018-0981</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Sathya Narayanan</surname><given-names>M. K.</given-names></name></name-alternatives><bio xml:lang="en"><p>Mukesh Kumar Sathya Narayanan, Scientist B, Research Officer </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-0719-0585</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Deka</surname><given-names>M.</given-names></name></name-alternatives><bio xml:lang="en"><p>Mrigen Deka, World Health Organization National Tuberculosis Consultant, Central Tuberculosis Division </p><p>New Delhi – 110011</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0369-6640</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Selvaraju</surname><given-names>S.</given-names></name></name-alternatives><bio xml:lang="en"><p>Sriram Selvaraju, Scientist E, Deputy Director </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0006-7873</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Santhanakrishnan</surname><given-names>R.</given-names></name></name-alternatives><bio xml:lang="en"><p>Rameshkumar Santhanakrishnan, Scientist F, Senior Deputy Director </p><p>Chennai – 600031</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9317-766X</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Krishnan</surname><given-names>R.</given-names></name></name-alternatives><bio xml:lang="en"><p>Rajendran Krishnan, Scientist E, Deputy Director </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1762-6424</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Chinnaiyan</surname><given-names>P.</given-names></name></name-alternatives><bio xml:lang="en"><p>Ponnuraja Chinnaiyan, Scientist F, Senior Deputy Director </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8526-2402</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Palaniyandi</surname><given-names>K.</given-names></name></name-alternatives><bio xml:lang="en"><p>Kannan Palaniyandi, Scientist E, Deputy Director </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4697-2115</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Vetrivel</surname><given-names>U.</given-names></name></name-alternatives><bio xml:lang="en"><p>Umashankar Vetrivel, Scientist E, Deputy Director </p><p>Chennai – 600031</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4500-8431</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Jeyakumar</surname><given-names>S. M.</given-names></name></name-alternatives><bio xml:lang="en"><p>Shanmugam Murugaiha Jeyakumar, Scientist F, Senior Deputy Director </p><p>Chennai – 600031</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7830-2840</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Natarajan</surname><given-names>S.</given-names></name></name-alternatives><bio xml:lang="en"><p>Saravanan Natarajan, Scientist E, Deputy Director </p><p>Chennai – 600031 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-5257-6553</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Mathur</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="en"><p>Alok Mathur, Additional Deputy Director General, Central Tuberculosis Division </p><p>New Delhi – 110011</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff xml:lang="en" id="aff-1"><institution>Medical Research-National Institute for Research in Tuberculosis (ICMR-NIRT)</institution><country>India</country></aff><aff xml:lang="en" id="aff-2"><institution>ICMR-NIRT</institution><country>India</country></aff><aff xml:lang="en" id="aff-3"><institution>Ministry of Health and Family Welfare</institution><country>India</country></aff><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>07</day><month>10</month><year>2024</year></pub-date><volume>1</volume><issue>1</issue><fpage>35</fpage><lpage>58</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Gopalan N., Newtonraj A., Elizabeth L.K., Shanmugam S.K., Ranganathan U.D., Muniyandi M., Ramraj B., Devaleenal B., Venkataraman A., Nagarajan K., Bethunaickan R., Sathya Narayanan M.K., Deka M., Selvaraju S., Santhanakrishnan R., Krishnan R., Chinnaiyan P., Palaniyandi K., Vetrivel U., Jeyakumar S.M., Natarajan S., Mathur A., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Gopalan N., Newtonraj A., Elizabeth L.K., Shanmugam S.K., Ranganathan U.D., Muniyandi M., Ramraj B., Devaleenal B., Venkataraman A., Nagarajan K., Bethunaickan R., Sathya Narayanan M.K., Deka M., Selvaraju S., Santhanakrishnan R., Krishnan R., Chinnaiyan P., Palaniyandi K., Vetrivel U., Jeyakumar S.M., Natarajan S., Mathur A.</copyright-holder><copyright-holder xml:lang="en">Gopalan N., Newtonraj A., Elizabeth L.K., Shanmugam S.K., Ranganathan U.D., Muniyandi M., Ramraj B., Devaleenal B., Venkataraman A., Nagarajan K., Bethunaickan R., Sathya Narayanan M.K., Deka M., Selvaraju S., Santhanakrishnan R., Krishnan R., Chinnaiyan P., Palaniyandi K., Vetrivel U., Jeyakumar S.M., Natarajan S., Mathur A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.bricshealthjournal.com/jour/article/view/7">https://www.bricshealthjournal.com/jour/article/view/7</self-uri><abstract><p>Tuberculosis (TB), the single most infectious killer deserves special attention in a focussed manner, to reduce morbidity and mortality. We describe the challenges in the four pillars of TB control: detect or diagnosis, treat, prevent, build and elaborate the success stories, listing out newer and advanced tools like artificial intelligence, whole genome sequencing, clustered regularly interspaced short palindromic repeats based technologies, one health approach and cost effectiveness strategies for an all- round reduction in TB control. Special problems posed by paediatric and extra-pulmonary TB are dealt with. Post TB lung sequalae, reverse zoonosis and behavioural modification that can influence catastrophic costs are explored. Use of molecular and genomic methods of TB detection has revolutionized TB care with increased sensitivity of diagnosis, and timely detection of drug resistance, saving many a precious lives. Undoubtedly, the need of the hour would be shortening TB treatment duration and comprehensive preventive strategies that simultaneously decrease both the incidence and prevalence of TB. The various schemes and initiatives undertaken by the Government of India including the Pradhan Mantri TB Mukt Bharat Abhiyaan – “TB free India” stand as a unique solution in the wake of eliminating TB. India has been extending its success stories to other countries as well, by creating platforms for multilateral research and multinational implementation. This manuscript gives a concise and comprehensive outlook of process involved in TB elimination, amalgamating the research evidences with the programmatic initiatives, enlisting the existing challenges, envisaging the current achievements, providing a road map for TB elimination.</p></abstract><kwd-group xml:lang="en"><kwd>TB programme</kwd><kwd>NTEP</kwd><kwd>TB</kwd><kwd>mycobacteriology</kwd><kwd>ATT</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Dickinson JM, Mitchison DA. In vitro studies on the choice of drugs for intermittent chemotherapy of tuberculosis. Tubercle. 1966;47:370-380. doi: 10.1016/S0041-3879(66)80022-3</mixed-citation><mixed-citation xml:lang="en">Dickinson JM, Mitchison DA. In vitro studies on the choice of drugs for intermittent chemotherapy of tuberculosis. Tubercle. 1966;47:370-380. doi: 10.1016/S0041-3879(66)80022-3</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Abbas AK, Andrew H. Lichtman, et al. Cellular and Molecular Immunology. 10th ed. Elsevier; 2022.</mixed-citation><mixed-citation xml:lang="en">Abbas AK, Andrew H. Lichtman, et al. Cellular and Molecular Immunology. 10th ed. Elsevier; 2022.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cabibbe AM, Sotgiu G, Izco S, Migliori GB. Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens. Eur Respir J. 2017;50(6):1702292. Published 2017 Dec 28. doi:10.1183/13993003.02292-2017</mixed-citation><mixed-citation xml:lang="en">Cabibbe AM, Sotgiu G, Izco S, Migliori GB. Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens. Eur Respir J. 2017;50(6):1702292. Published 2017 Dec 28. doi:10.1183/13993003.02292-2017</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Cabibbe AM, Spitaleri A, Battaglia S, et al. Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples. J Clin Microbiol. 2020;58(10):e00632-20. Published 2020 Sep 22. doi:10.1128/JCM.00632-20</mixed-citation><mixed-citation xml:lang="en">Cabibbe AM, Spitaleri A, Battaglia S, et al. Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples. J Clin Microbiol. 2020;58(10):e00632-20. Published 2020 Sep 22. doi:10.1128/JCM.00632-20</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Shanmugam SK, Kumar N, Sembulingam T, et al. Mycobacterium tuberculosis Lineages Associated with Mutations and Drug Resistance in Isolates from India. Microbiol Spectr. 2022;10(3):e0159421. doi:10.1128/spectrum.01594-21</mixed-citation><mixed-citation xml:lang="en">Shanmugam SK, Kumar N, Sembulingam T, et al. Mycobacterium tuberculosis Lineages Associated with Mutations and Drug Resistance in Isolates from India. Microbiol Spectr. 2022;10(3):e0159421. doi:10.1128/spectrum.01594-21</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Jayaprakasam M, Pandey RM, Choudhary H, et al. Evaluation of molecular diagnostic test for detection of adult pulmonary tuberculosis: A generic protocol. Indian J Med Res. 2024;159(2):246-253. doi:10.4103/ijmr.ijmr_2316_23</mixed-citation><mixed-citation xml:lang="en">Jayaprakasam M, Pandey RM, Choudhary H, et al. Evaluation of molecular diagnostic test for detection of adult pulmonary tuberculosis: A generic protocol. Indian J Med Res. 2024;159(2):246-253. doi:10.4103/ijmr.ijmr_2316_23</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Grzybowski S, Enarson D. Le devenir des tuberculeux pulmonaires dans diverses circonstances de programmes de traitement [Results in pulmonary tuberculosis patients under various treatment program conditions]. Bull Int Union Tuberc. 1978;53(2):70-75.</mixed-citation><mixed-citation xml:lang="en">Grzybowski S, Enarson D. Le devenir des tuberculeux pulmonaires dans diverses circonstances de programmes de traitement [Results in pulmonary tuberculosis patients under various treatment program conditions]. Bull Int Union Tuberc. 1978;53(2):70-75.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tuberculosis Chemotherapy Centre. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ. 1959;21(1):51-144.</mixed-citation><mixed-citation xml:lang="en">Tuberculosis Chemotherapy Centre. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ. 1959;21(1):51-144.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle. 1983;64(2):73-91. doi:10.1016/0041-3879(83)90032-6</mixed-citation><mixed-citation xml:lang="en">Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle. 1983;64(2):73-91. doi:10.1016/0041-3879(83)90032-6</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Tuberculosis Research Centre, Chennai (2002) Shortening short course chemotherapy: a randomized clinical trial for the treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian Journal of Tuberculosis, (1):27-38. ISSN 0019-5705</mixed-citation><mixed-citation xml:lang="en">Tuberculosis Research Centre, Chennai (2002) Shortening short course chemotherapy: a randomized clinical trial for the treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian Journal of Tuberculosis, (1):27-38. ISSN 0019-5705</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Intermittent treatment of pulmonary tuberculosis: A Concurrent Comparison of Twice-weekly Isoniazid plus Streptomycin and Daily Isoniazid plus p-Aminosalicylic Acid in Domiciliary Treatment. The Lancet. 1963; 281(7290):1078-1080. doi:10.1016/S0140-6736(63)92115-9</mixed-citation><mixed-citation xml:lang="en">Intermittent treatment of pulmonary tuberculosis: A Concurrent Comparison of Twice-weekly Isoniazid plus Streptomycin and Daily Isoniazid plus p-Aminosalicylic Acid in Domiciliary Treatment. The Lancet. 1963; 281(7290):1078-1080. doi:10.1016/S0140-6736(63)92115-9</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Controlled comparison of oral twice-weekly and oral daily isoniazid plus PAS in newly diagnosed pulmonary tuberculosis. Br Med J. 1973;2(5857):7-11.</mixed-citation><mixed-citation xml:lang="en">Controlled comparison of oral twice-weekly and oral daily isoniazid plus PAS in newly diagnosed pulmonary tuberculosis. Br Med J. 1973;2(5857):7-11.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med. 2010;181(7):743-751. doi:10.1164/rccm.200903-0439OC</mixed-citation><mixed-citation xml:lang="en">Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med. 2010;181(7):743-751. doi:10.1164/rccm.200903-0439OC</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One. 2013;8(7):e67030. Published 2013 Jul 3. doi:10.1371/journal.pone.0067030</mixed-citation><mixed-citation xml:lang="en">Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One. 2013;8(7):e67030. Published 2013 Jul 3. doi:10.1371/journal.pone.0067030</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011;53(7):716-724. doi:10.1093/cid/cir447</mixed-citation><mixed-citation xml:lang="en">Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011;53(7):716-724. doi:10.1093/cid/cir447</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Velayutham B, Jawahar MS, Nair D, et al. 4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India – a randomised clinical trial. Trop Med Int Health. 2020;25(4):483-495. doi:10.1111/tmi.13371</mixed-citation><mixed-citation xml:lang="en">Velayutham B, Jawahar MS, Nair D, et al. 4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India – a randomised clinical trial. Trop Med Int Health. 2020;25(4):483-495. doi:10.1111/tmi.13371</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gopalan N, Santhanakrishnan RK, Palaniappan AN, et al. Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(4):485-493. doi:10.1001/jamainternmed.2018.0141</mixed-citation><mixed-citation xml:lang="en">Gopalan N, Santhanakrishnan RK, Palaniappan AN, et al. Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(4):485-493. doi:10.1001/jamainternmed.2018.0141</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther. 2016;13:34. Published 2016 Sep 26. doi:10.1186/s12981-016-0118-7</mixed-citation><mixed-citation xml:lang="en">Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther. 2016;13:34. Published 2016 Sep 26. doi:10.1186/s12981-016-0118-7</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Narendran G, Menon PA, Venkatesan P, et al. Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. Clin Infect Dis. 2014;59(12):1798-1804. doi:10.1093/cid/ciu674</mixed-citation><mixed-citation xml:lang="en">Narendran G, Menon PA, Venkatesan P, et al. Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. Clin Infect Dis. 2014;59(12):1798-1804. doi:10.1093/cid/ciu674</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial [published correction appears in Lancet. 2022 Nov 19;400(10365):1766. doi: 10.1016/S0140-6736(22)02307-8]. Lancet. 2022;400(10366):1858-1868. doi:10.1016/S0140-6736(22)02078-5</mixed-citation><mixed-citation xml:lang="en">Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial [published correction appears in Lancet. 2022 Nov 19;400(10365):1766. doi: 10.1016/S0140-6736(22)02307-8]. Lancet. 2022;400(10366):1858-1868. doi:10.1016/S0140-6736(22)02078-5</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Imperial MZ, Nahid P, Phillips PPJ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis [published correction appears in Nat Med. 2019 Jan;25(1):190. doi: 10.1038/s41591-018-0294-1]. Nat Med. 2018;24(11):1708-1715. doi:10.1038/s41591-018-0224-2</mixed-citation><mixed-citation xml:lang="en">Imperial MZ, Nahid P, Phillips PPJ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis [published correction appears in Nat Med. 2019 Jan;25(1):190. doi: 10.1038/s41591-018-0294-1]. Nat Med. 2018;24(11):1708-1715. doi:10.1038/s41591-018-0224-2</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Gopalan N, Srinivasalu VA, Chinnayan P, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. PloS one. 2021;16(9):e0257647.</mixed-citation><mixed-citation xml:lang="en">Gopalan N, Srinivasalu VA, Chinnayan P, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. PloS one. 2021;16(9):e0257647.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021;384(18):1705-1718. doi:10.1056/NEJMoa2033400</mixed-citation><mixed-citation xml:lang="en">Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021;384(18):1705-1718. doi:10.1056/NEJMoa2033400</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Perumal Kannabiran B, Palaniappan NA, Manoharan T, et al. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024;11(3):ofae034. Published 2024 Feb 2. doi:10.1093/ofid/ofae034</mixed-citation><mixed-citation xml:lang="en">Perumal Kannabiran B, Palaniappan NA, Manoharan T, et al. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024;11(3):ofae034. Published 2024 Feb 2. doi:10.1093/ofid/ofae034</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Narendran G, Andrade BB, Porter BO, et al. Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS One. 2013;8(5):e63541. Published 2013 May 17. doi:10.1371/journal.pone.0063541</mixed-citation><mixed-citation xml:lang="en">Narendran G, Andrade BB, Porter BO, et al. Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS One. 2013;8(5):e63541. Published 2013 May 17. doi:10.1371/journal.pone.0063541</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Singh UB, Singh M, Rodrigues C, et al. Multi-centric evaluation of Truenat MTB and MTB-RIF Dx assays for diagnosis of extrapulmonary tuberculosis. Sci Rep. 2024;14(1):15680. Published 2024 Jul 8. doi:10.1038/s41598-024-64688-z</mixed-citation><mixed-citation xml:lang="en">Singh UB, Singh M, Rodrigues C, et al. Multi-centric evaluation of Truenat MTB and MTB-RIF Dx assays for diagnosis of extrapulmonary tuberculosis. Sci Rep. 2024;14(1):15680. Published 2024 Jul 8. doi:10.1038/s41598-024-64688-z</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Purohit MR, Purohit R, Mustafa T. Patient Health Seeking and Diagnostic Delay in Extrapulmonary Tuberculosis: A Hospital Based Study from Central India. Tuberc Res Treat. 2019;2019:4840561. Published 2019 Feb 3. doi:10.1155/2019/4840561</mixed-citation><mixed-citation xml:lang="en">Purohit MR, Purohit R, Mustafa T. Patient Health Seeking and Diagnostic Delay in Extrapulmonary Tuberculosis: A Hospital Based Study from Central India. Tuberc Res Treat. 2019;2019:4840561. Published 2019 Feb 3. doi:10.1155/2019/4840561</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Rasouli MR, Mirkoohi M, Vaccaro AR, et al. Spinal tuberculosis: diagnosis and management. Asian Spine J. 2012;6(4):294-308. doi:10.4184/asj.2012.6.4.294</mixed-citation><mixed-citation xml:lang="en">Rasouli MR, Mirkoohi M, Vaccaro AR, et al. Spinal tuberculosis: diagnosis and management. Asian Spine J. 2012;6(4):294-308. doi:10.4184/asj.2012.6.4.294</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Paradkar MS, Devaleenal D B, Mvalo T, et al. Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial. Clin Infect Dis. 2022;75(9):1594-1601. doi:10.1093/cid/ciac208</mixed-citation><mixed-citation xml:lang="en">Paradkar MS, Devaleenal D B, Mvalo T, et al. Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial. Clin Infect Dis. 2022;75(9):1594-1601. doi:10.1093/cid/ciac208</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Hissar S, Velayutham B, Tamizhselvan M, et al. Efficacy and Tolerability of a 4-month Ofloxacin-Containing Regimen Compared to a 6-month Regimen in The Treatment of Patients With Superficial Lymph Node Tuberculosis: a Randomized Trial. BMC Infect Dis. 2024,729 (2024). https://doi.org/10.1186/s12879-024-09511-w</mixed-citation><mixed-citation xml:lang="en">Hissar S, Velayutham B, Tamizhselvan M, et al. Efficacy and Tolerability of a 4-month Ofloxacin-Containing Regimen Compared to a 6-month Regimen in The Treatment of Patients With Superficial Lymph Node Tuberculosis: a Randomized Trial. BMC Infect Dis. 2024,729 (2024). https://doi.org/10.1186/s12879-024-09511-w</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas TA. Tuberculosis in Children. Pediatr Clin North Am. 2017;64(4):893-909. doi:10.1016/j.pcl.2017.03.010</mixed-citation><mixed-citation xml:lang="en">Thomas TA. Tuberculosis in Children. Pediatr Clin North Am. 2017;64(4):893-909. doi:10.1016/j.pcl.2017.03.010</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Seddon JA, Shingadia D. Epidemiology and disease burden of tuberculosis in children: a global perspective. Infect Drug Resist. 2014;7:153-165. Published 2014 Jun 18. doi:10.2147/IDR.S45090</mixed-citation><mixed-citation xml:lang="en">Seddon JA, Shingadia D. Epidemiology and disease burden of tuberculosis in children: a global perspective. Infect Drug Resist. 2014;7:153-165. Published 2014 Jun 18. doi:10.2147/IDR.S45090</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Siamisang K, Rankgoane-Pono G, Madisa TM, et al. Pediatric tuberculosis outcomes and factors associated with unfavorable treatment outcomes in Botswana, 2008-2019: a retrospective analysis. BMC Public Health. 2022;22(1):2020. Published 2022 Nov 4. doi:10.1186/s12889-022-14477-y</mixed-citation><mixed-citation xml:lang="en">Siamisang K, Rankgoane-Pono G, Madisa TM, et al. Pediatric tuberculosis outcomes and factors associated with unfavorable treatment outcomes in Botswana, 2008-2019: a retrospective analysis. BMC Public Health. 2022;22(1):2020. Published 2022 Nov 4. doi:10.1186/s12889-022-14477-y</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Berti E, Galli L, Venturini E, de Martini M, et al. Tuberculosis in childhood: a systematic review of national and international guidelines. BMC Infect Dis. 2014;14 Suppl 1(Suppl 1):S3. doi:10.1186/1471-2334-14-S1-S3</mixed-citation><mixed-citation xml:lang="en">Berti E, Galli L, Venturini E, de Martini M, et al. Tuberculosis in childhood: a systematic review of national and international guidelines. BMC Infect Dis. 2014;14 Suppl 1(Suppl 1):S3. doi:10.1186/1471-2334-14-S1-S3</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez L, Cords O, Horsburgh CR, Andrews JR; Pediatric TB Contact Studies Consortium. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973-984. doi:10.1016/S0140-6736(20)30166-5</mixed-citation><mixed-citation xml:lang="en">Martinez L, Cords O, Horsburgh CR, Andrews JR; Pediatric TB Contact Studies Consortium. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973-984. doi:10.1016/S0140-6736(20)30166-5</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials. 2018;19(1):237. Published 2018 Apr 19. doi:10.1186/s13063-018-2608-5</mixed-citation><mixed-citation xml:lang="en">Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials. 2018;19(1):237. Published 2018 Apr 19. doi:10.1186/s13063-018-2608-5</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Turkova A, Wills GH, Wobudeya E, et al. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. N Engl J Med. 2022;386(10):911-922. doi:10.1056/NEJMoa2104535</mixed-citation><mixed-citation xml:lang="en">Turkova A, Wills GH, Wobudeya E, et al. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. N Engl J Med. 2022;386(10):911-922. doi:10.1056/NEJMoa2104535</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Basu Roy R, Whittaker E, Kampmann B. Current understanding of the immune response to tuberculosis in children. Curr Opin Infect Dis. 2012;25(3):250-257. doi:</mixed-citation><mixed-citation xml:lang="en">Basu Roy R, Whittaker E, Kampmann B. Current understanding of the immune response to tuberculosis in children. Curr Opin Infect Dis. 2012;25(3):250-257. doi:</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Bhargava A, Bhargava M, Meher A, et al. Nutritional support for adult patients with microbiologically confirmed pulmonary tuberculosis: outcomes in a programmatic cohort nested within the RATIONS trial in Jharkhand, India. Lancet Glob Health. 2023;11(9):e1402-e1411. doi:10.1016/S2214-109X(23)00324-8</mixed-citation><mixed-citation xml:lang="en">Bhargava A, Bhargava M, Meher A, et al. Nutritional support for adult patients with microbiologically confirmed pulmonary tuberculosis: outcomes in a programmatic cohort nested within the RATIONS trial in Jharkhand, India. Lancet Glob Health. 2023;11(9):e1402-e1411. doi:10.1016/S2214-109X(23)00324-8</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Rouf A, Masoodi MA, Dar MM, et al. Depression among Tuberculosis patients and its association with treatment outcomes in district Srinagar. J Clin Tuberc Other Mycobact Dis. 2021;25:100281. Published 2021 Nov 15. doi:10.1016/j.jctube.2021.100281</mixed-citation><mixed-citation xml:lang="en">Rouf A, Masoodi MA, Dar MM, et al. Depression among Tuberculosis patients and its association with treatment outcomes in district Srinagar. J Clin Tuberc Other Mycobact Dis. 2021;25:100281. Published 2021 Nov 15. doi:10.1016/j.jctube.2021.100281</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Suryavanshi N, Sane M, Gaikwad S, et al. Assessment of persistent depression among TB patients. Int J Tuberc Lung Dis. 2020;24(11):1208-1211. doi:10.5588/ijtld.20.0231</mixed-citation><mixed-citation xml:lang="en">Suryavanshi N, Sane M, Gaikwad S, et al. Assessment of persistent depression among TB patients. Int J Tuberc Lung Dis. 2020;24(11):1208-1211. doi:10.5588/ijtld.20.0231</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz-Grosso P, Cachay R, de la Flor A, et al. Association between tuberculosis and depression on negative outcomes of tuberculosis treatment: A systematic review and meta-analysis. PLoS One. 2020;15(1):e0227472. Published 2020 Jan 10. doi:10.1371/journal.pone.0227472</mixed-citation><mixed-citation xml:lang="en">Ruiz-Grosso P, Cachay R, de la Flor A, et al. Association between tuberculosis and depression on negative outcomes of tuberculosis treatment: A systematic review and meta-analysis. PLoS One. 2020;15(1):e0227472. Published 2020 Jan 10. doi:10.1371/journal.pone.0227472</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Rouf A, Masoodi MA, Dar MM, et al. Depression among Tuberculosis patients and its association with treatment outcomes in district Srinagar. J Clin Tuberc Other Mycobact Dis. 2021;25:100281. Published 2021 Nov 15. doi:10.1016/j.jctube.2021.100281</mixed-citation><mixed-citation xml:lang="en">Rouf A, Masoodi MA, Dar MM, et al. Depression among Tuberculosis patients and its association with treatment outcomes in district Srinagar. J Clin Tuberc Other Mycobact Dis. 2021;25:100281. Published 2021 Nov 15. doi:10.1016/j.jctube.2021.100281</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Panati D, Chittooru CS, Madarapu YR, Gorantla AK. Effect of depression on treatment adherence among elderly tuberculosis patients: A prospective interventional study. Clin Epidemiol Glob Health. 2023;22:101338. doi: 10.1016/j.cegh.2023.101338</mixed-citation><mixed-citation xml:lang="en">Panati D, Chittooru CS, Madarapu YR, Gorantla AK. Effect of depression on treatment adherence among elderly tuberculosis patients: A prospective interventional study. Clin Epidemiol Glob Health. 2023;22:101338. doi: 10.1016/j.cegh.2023.101338</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Maroof M, Pamei G, Bhatt M, et al. Drug adherence to anti-tubercular treatment during COVID-19 lockdown in Haldwani block of Nainital district. Indian J Community Health. 2022;34:535–541.</mixed-citation><mixed-citation xml:lang="en">Maroof M, Pamei G, Bhatt M, et al. Drug adherence to anti-tubercular treatment during COVID-19 lockdown in Haldwani block of Nainital district. Indian J Community Health. 2022;34:535–541.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Ragan EJ, Kleinman MB, Sweigart B, et al. The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2020;24(1):73-82. doi:10.5588/ijtld.19.0080</mixed-citation><mixed-citation xml:lang="en">Ragan EJ, Kleinman MB, Sweigart B, et al. The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2020;24(1):73-82. doi:10.5588/ijtld.19.0080</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Cox SR, Gupte AN, Thomas B, et al. Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men. Int J Tuberc Lung Dis. 2021;25(3):182-190. doi:10.5588/ijtld.20.0778</mixed-citation><mixed-citation xml:lang="en">Cox SR, Gupte AN, Thomas B, et al. Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men. Int J Tuberc Lung Dis. 2021;25(3):182-190. doi:10.5588/ijtld.20.0778</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas B, Watson B, Senthil EK, et al. Alcohol intervention strategy among tuberculosis patients: a pilot study from South India. Int J Tuberc Lung Dis. 2017;21(8):947-952. doi:10.5588/ijtld.16.0693</mixed-citation><mixed-citation xml:lang="en">Thomas B, Watson B, Senthil EK, et al. Alcohol intervention strategy among tuberculosis patients: a pilot study from South India. Int J Tuberc Lung Dis. 2017;21(8):947-952. doi:10.5588/ijtld.16.0693</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Suhadev M, Thomas BE, Raja Sakthivel M, et al. Alcohol use disorders (AUD) among tuberculosis patients: a study from Chennai, South India. PLoS One. 2011;6(5):e19485. doi:10.1371/journal.pone.0019485</mixed-citation><mixed-citation xml:lang="en">Suhadev M, Thomas BE, Raja Sakthivel M, et al. Alcohol use disorders (AUD) among tuberculosis patients: a study from Chennai, South India. PLoS One. 2011;6(5):e19485. doi:10.1371/journal.pone.0019485</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Kan CK, Ragan EJ, Sarkar S, et al. Alcohol use and tuberculosis clinical presentation at the time of diagnosis in Puducherry and Tamil Nadu, India. PLoS One. 2020;15(12):e0240595. Published 2020 Dec 17. doi:10.1371/journal.pone.0240595</mixed-citation><mixed-citation xml:lang="en">Kan CK, Ragan EJ, Sarkar S, et al. Alcohol use and tuberculosis clinical presentation at the time of diagnosis in Puducherry and Tamil Nadu, India. PLoS One. 2020;15(12):e0240595. Published 2020 Dec 17. doi:10.1371/journal.pone.0240595</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Thapa P, Kamath R, Shetty BK, et al. Prevalence and Associated Factors of Alcoholism among Tuberculosis Patients in Udupi Taluk, Karnataka, India: A Cross Sectional Study. J Nepal Health Res Counc. 2014;12(28):177-181.</mixed-citation><mixed-citation xml:lang="en">Thapa P, Kamath R, Shetty BK, et al. Prevalence and Associated Factors of Alcoholism among Tuberculosis Patients in Udupi Taluk, Karnataka, India: A Cross Sectional Study. J Nepal Health Res Counc. 2014;12(28):177-181.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Thummar PD, Rupani MP. Prevalence and predictors of hazardous alcohol use among tuberculosis patients: The need for a policy on joint tuberculosis-alcohol collaborative activities in India. Alcohol. 2020;86:113-119. doi:10.1016/j.alcohol.2020.03.006</mixed-citation><mixed-citation xml:lang="en">Thummar PD, Rupani MP. Prevalence and predictors of hazardous alcohol use among tuberculosis patients: The need for a policy on joint tuberculosis-alcohol collaborative activities in India. Alcohol. 2020;86:113-119. doi:10.1016/j.alcohol.2020.03.006</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Wyszewianski L. Financially catastrophic and high-cost cases: definitions, distinctions, and their implications for policy formulation. Inquiry. 1986;23(4):382-394.</mixed-citation><mixed-citation xml:lang="en">Wyszewianski L. Financially catastrophic and high-cost cases: definitions, distinctions, and their implications for policy formulation. Inquiry. 1986;23(4):382-394.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Puteh SEW, Almualm Y. Catastrophic health expenditure among developing countries. Health Syst Policy Res. 2017;4:1.</mixed-citation><mixed-citation xml:lang="en">Puteh SEW, Almualm Y. Catastrophic health expenditure among developing countries. Health Syst Policy Res. 2017;4:1.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Rajeswari R, Balasubramanian R, Muniyandi M, et al. Socio-economic impact of tuberculosis on patients and family in India. Int J Tuberc Lung Dis. 1999;3(10):869-877.</mixed-citation><mixed-citation xml:lang="en">Rajeswari R, Balasubramanian R, Muniyandi M, et al. Socio-economic impact of tuberculosis on patients and family in India. Int J Tuberc Lung Dis. 1999;3(10):869-877.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Muniyandi M, Ramachandran R, Balasubramanian R, Narayanan PR. Socio-economic dimensions of tuberculosis control: review of studies over two decades from Tuberculosis Research Center. J Commun Dis. 2006;38(3):204-215.</mixed-citation><mixed-citation xml:lang="en">Muniyandi M, Ramachandran R, Balasubramanian R, Narayanan PR. Socio-economic dimensions of tuberculosis control: review of studies over two decades from Tuberculosis Research Center. J Commun Dis. 2006;38(3):204-215.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Muniyandi M, Thomas BE, Karikalan N, et al. Catastrophic costs due to tuberculosis in South India: comparison between active and passive case finding. Trans R Soc Trop Med Hyg. 2020;114(3):185-192. doi:10.1093/trstmh/trz127</mixed-citation><mixed-citation xml:lang="en">Muniyandi M, Thomas BE, Karikalan N, et al. Catastrophic costs due to tuberculosis in South India: comparison between active and passive case finding. Trans R Soc Trop Med Hyg. 2020;114(3):185-192. doi:10.1093/trstmh/trz127</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Rucsineanu O, Agbassi P, Herrera R, et al. Shorter TB treatment regimens should be safer as well. Public Health Action. 2023;13(3):104-106. doi:10.5588/pha.23.0026</mixed-citation><mixed-citation xml:lang="en">Rucsineanu O, Agbassi P, Herrera R, et al. Shorter TB treatment regimens should be safer as well. Public Health Action. 2023;13(3):104-106. doi:10.5588/pha.23.0026</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Padmapriyadarsini C, Vohra V, Bhatnagar A, et al. Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clin Infect Dis. Published online June 29, 2022. doi:10.1093/cid/ciac528</mixed-citation><mixed-citation xml:lang="en">Padmapriyadarsini C, Vohra V, Bhatnagar A, et al. Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clin Infect Dis. Published online June 29, 2022. doi:10.1093/cid/ciac528</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Putra ON, Yulistiani Y, Soedarsono S, Subay S. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review. Int J Mycobacteriol. 2023;12(1):1-9. doi:10.4103/ijmy.ijmy_217_22</mixed-citation><mixed-citation xml:lang="en">Putra ON, Yulistiani Y, Soedarsono S, Subay S. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review. Int J Mycobacteriol. 2023;12(1):1-9. doi:10.4103/ijmy.ijmy_217_22</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Ryckman TS, Schumacher SG, Lienhardt C, et al. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis. Lancet Glob Health. 2024;12(6):e995-e1004. doi:10.1016/S2214-109X(24)00088-3</mixed-citation><mixed-citation xml:lang="en">Ryckman TS, Schumacher SG, Lienhardt C, et al. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis. Lancet Glob Health. 2024;12(6):e995-e1004. doi:10.1016/S2214-109X(24)00088-3</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Muniyandi M, Karikalan N, Velayutham B, et al. Cost Effectiveness of a Shorter Moxifloxacin Based Regimen for Treating Drug Sensitive Tuberculosis in India. Trop Med Infect Dis. 2022;7(10):288. Published 2022 Oct 8. doi:10.3390/tropicalmed7100288</mixed-citation><mixed-citation xml:lang="en">Muniyandi M, Karikalan N, Velayutham B, et al. Cost Effectiveness of a Shorter Moxifloxacin Based Regimen for Treating Drug Sensitive Tuberculosis in India. Trop Med Infect Dis. 2022;7(10):288. Published 2022 Oct 8. doi:10.3390/tropicalmed7100288</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Rosu L, Madan JJ, Tomeny EM, et al. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial [published correction appears in Lancet Glob Health. 2023 Feb;11(2):e196. doi: 10.1016/S2214-109X(23)00009-8]. Lancet Glob Health. 2023;11(2):e265-e277. doi:10.1016/S2214-109X(22)00498-3</mixed-citation><mixed-citation xml:lang="en">Rosu L, Madan JJ, Tomeny EM, et al. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial [published correction appears in Lancet Glob Health. 2023 Feb;11(2):e196. doi: 10.1016/S2214-109X(23)00009-8]. Lancet Glob Health. 2023;11(2):e265-e277. doi:10.1016/S2214-109X(22)00498-3</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Muniyandi M, Ramesh PM, Wells WA, et al. The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB. Trop Med Infect Dis. 2023;8(8):411. Published 2023 Aug 11. doi:10.3390/tropicalmed8080411</mixed-citation><mixed-citation xml:lang="en">Muniyandi M, Ramesh PM, Wells WA, et al. The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB. Trop Med Infect Dis. 2023;8(8):411. Published 2023 Aug 11. doi:10.3390/tropicalmed8080411</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Allwood BW, van der Zalm MM, Amaral AFS, et al. Post-tuberculosis lung health: perspectives from the First International Symposium. Int J Tuberc Lung Dis. 2020;24(8):820-828. doi:10.5588/ijtld.20.0067</mixed-citation><mixed-citation xml:lang="en">Allwood BW, van der Zalm MM, Amaral AFS, et al. Post-tuberculosis lung health: perspectives from the First International Symposium. Int J Tuberc Lung Dis. 2020;24(8):820-828. doi:10.5588/ijtld.20.0067</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Fox GJ, Nguyen VN, Dinh NS, et al. Post-treatment Mortality Among Patients With Tuberculosis: A Prospective Cohort Study of 10 964 Patients in Vietnam. Clin Infect Dis. 2019;68(8):1359-1366. doi:10.1093/cid/ciy665</mixed-citation><mixed-citation xml:lang="en">Fox GJ, Nguyen VN, Dinh NS, et al. Post-treatment Mortality Among Patients With Tuberculosis: A Prospective Cohort Study of 10 964 Patients in Vietnam. Clin Infect Dis. 2019;68(8):1359-1366. doi:10.1093/cid/ciy665</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar AKH, Kadam A, Karunaianantham R, et al. Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis. Ther Drug Monit. 2024;46(3):370-375. doi:10.1097/FTD.0000000000001149</mixed-citation><mixed-citation xml:lang="en">Kumar AKH, Kadam A, Karunaianantham R, et al. Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis. Ther Drug Monit. 2024;46(3):370-375. doi:10.1097/FTD.0000000000001149</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Swaminathan S, Menon PA, Gopalan N, et al. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One. 2012;7(12):e47400. doi:10.1371/journal.pone.0047400</mixed-citation><mixed-citation xml:lang="en">Swaminathan S, Menon PA, Gopalan N, et al. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One. 2012;7(12):e47400. doi:10.1371/journal.pone.0047400</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Moonan PK, Nair SA, Agarwal R, et al. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India. BMJ Glob Health. 2018;3:e001135. doi:10.1136/bmjgh-2018-001135</mixed-citation><mixed-citation xml:lang="en">Moonan PK, Nair SA, Agarwal R, et al. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India. BMJ Glob Health. 2018;3:e001135. doi:10.1136/ bmjgh-2018-001135</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Anurag Bhargava. The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India. The Lancet Regional Health – Southeast Asia. Published 2024 May 12. doi:10.1016/j.lansea.2024.100422</mixed-citation><mixed-citation xml:lang="en">Anurag Bhargava. The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India. The Lancet Regional Health – Southeast Asia. Published 2024 May 12. doi:10.1016/j.lansea.2024.100422</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Selvaraju S, Velayutham B, Rao R, et al. Prevalence and factors associated with tuberculosis infection in India. J Infect Public Health. 2023;16(12):2058-2065. doi:10.1016/j.jiph.2023.10.009</mixed-citation><mixed-citation xml:lang="en">Selvaraju S, Velayutham B, Rao R, et al. Prevalence and factors associated with tuberculosis infection in India. J Infect Public Health. 2023;16(12):2058-2065. doi:10.1016/j.jiph.2023.10.009</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Prasad R, Singh A, Gupta N. Adverse drug reactions in tuberculosis and management. Indian J Tuberc. 2019;66(4):520-532. doi:10.1016/j.ijtb.2019.11.005</mixed-citation><mixed-citation xml:lang="en">Prasad R, Singh A, Gupta N. Adverse drug reactions in tuberculosis and management. Indian J Tuberc. 2019;66(4):520-532. doi:10.1016/j.ijtb.2019.11.005</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Mukherjee A, Gowtham L, Kabra SK, et al. Pharmacokinetic-Pharmacodynamic (PKPD) Analysis of Second-Line Anti-Tubercular Drugs in Indian Children with Multi-Drug Resistance. Indian J Pediatr. Published online May 28, 2024. doi:10.1007/s12098-024-05135-9</mixed-citation><mixed-citation xml:lang="en">Mukherjee A, Gowtham L, Kabra SK, et al. Pharmacokinetic-Pharmacodynamic (PKPD) Analysis of Second-Line Anti-Tubercular Drugs in Indian Children with MultiDrug Resistance. Indian J Pediatr. Published online May 28, 2024. doi:10.1007/s12098-024-05135-9</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Jeyakumar SM, Bhui NK, Singla N, et al. Long-Term Intake of Linezolid Elevates Drug Exposure and Reduces Drug Clearance and Elimination in Adults With DrugResistant Pulmonary Tuberculosis. Ther Drug Monit. 2023;45(6):754-759. doi:10.1097/FTD.0000000000001111</mixed-citation><mixed-citation xml:lang="en">Jeyakumar SM, Bhui NK, Singla N, et al. Long-Term Intake of Linezolid Elevates Drug Exposure and Reduces Drug Clearance and Elimination in Adults With DrugResistant Pulmonary Tuberculosis. Ther Drug Monit. 2023;45(6):754-759. doi:10.1097/FTD.0000000000001111</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Hemanth Kumar AK, Narendran G, Kumar RS, et al. RMP exposure is lower in HIV-infected TB patients receiving intermittent than daily anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2015;19(7):805-807. doi:10.5588/ijtld.14.0702</mixed-citation><mixed-citation xml:lang="en">Hemanth Kumar AK, Narendran G, Kumar RS, et al. RMP exposure is lower in HIVinfected TB patients receiving intermittent than daily anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2015;19(7):805-807. doi:10.5588/ijtld.14.0702</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Moore DA. Future prospects for the MODS assay in multidrug-resistant tuberculosis diagnosis. Future Microbiol. 2007;2(2):97-101. doi:10.2217/17460913.2.2.97</mixed-citation><mixed-citation xml:lang="en">Moore DA. Future prospects for the MODS assay in multidrug-resistant tuberculosis diagnosis. Future Microbiol. 2007;2(2):97-101. doi:10.2217/17460913.2.2.97</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Bwanga F, Hoffner S, Haile M, Joloba ML. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis. 2009;9:67. Published 2009 May 20. doi:10.1186/1471-2334-9-67</mixed-citation><mixed-citation xml:lang="en">Bwanga F, Hoffner S, Haile M, Joloba ML. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis. 2009;9:67. Published 2009 May 20. doi:10.1186/1471-2334-9-67</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Vukugah TA, Ntoh VN, Akoku DA, et al. Research Questions and Priorities for Pediatric Tuberculosis: A Survey of Published Systematic Reviews and Meta-Analyses. Tuberc Res Treat. 2022;2022:1686047. Published 2022 Feb 7. doi:10.1155/2022/1686047</mixed-citation><mixed-citation xml:lang="en">Vukugah TA, Ntoh VN, Akoku DA, et al. Research Questions and Priorities for Pediatric Tuberculosis: A Survey of Published Systematic Reviews and Meta-Analyses. Tuberc Res Treat. 2022;2022:1686047. Published 2022 Feb 7. doi:10.1155/2022/1686047</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">McKenna L, Sari AH, Mane S, et al. Pediatric Tuberculosis Research and Development: Progress, Priorities and Funding Opportunities. Pathogens. 2022;11(2):128. Published 2022 Jan 21. doi:10.3390/pathogens11020128</mixed-citation><mixed-citation xml:lang="en">McKenna L, Sari AH, Mane S, et al. Pediatric Tuberculosis Research and Development: Progress, Priorities and Funding Opportunities. Pathogens. 2022;11(2):128. Published 2022 Jan 21. doi:10.3390/pathogens11020128</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnan R, Thiruvengadam K, Jayabal L, et al. An influence of dew point temperature on the occurrence of Mycobacterium tuberculosis disease in Chennai, India. Sci Rep. 2022 Apr 12;12(1):6147. doi: 10.1038/s41598-022-10111-4.</mixed-citation><mixed-citation xml:lang="en">Krishnan R, Thiruvengadam K, Jayabal L, et al. An influence of dew point temperature on the occurrence of Mycobacterium tuberculosis disease in Chennai, India. Sci Rep. 2022 Apr 12;12(1):6147. doi: 10.1038/s41598-022-10111-4.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Shewade HD, Frederick A, Kiruthika G, et al. The First Differentiated TB Care Model From India: Delays and Predictors of Losses in the Care Cascade. Glob Health Sci Pract. 2023;11(2):e2200505. Published 2023 Apr 28. doi:10.9745/GHSP-D-22-00505 Apr 28;11(2):e2200505.</mixed-citation><mixed-citation xml:lang="en">Shewade HD, Frederick A, Kiruthika G, et al. The First Differentiated TB Care Model From India: Delays and Predictors of Losses in the Care Cascade. Glob Health Sci Pract. 2023;11(2):e2200505. Published 2023 Apr 28. doi:10.9745/GHSP-D-22-00505Apr 28;11(2):e2200505.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
